Should I buy or sell Alimera Sciences stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Alimera Sciences in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ALIM shares. View ALIM analyst ratings or view top-rated stocks .

What is Alimera Sciences' stock price target for 2024?

2 equities research analysts have issued 12 month target prices for Alimera Sciences' stock. Their ALIM share price targets range from $5.00 to $8.00. On average, they expect the company's stock price to reach $6.50 in the next year. This suggests a possible upside of 110.7% from the stock's current price. View analysts price targets for ALIM or view top-rated stocks among Wall Street analysts .

How have ALIM shares performed in 2023?

Alimera Sciences' stock was trading at $2.71 at the beginning of 2023. Since then, ALIM stock has increased by 13.8% and is now trading at $3.0850. View the best growth stocks for 2023 here .

When is Alimera Sciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, March 29th 2024. View our ALIM earnings forecast .

How were Alimera Sciences' earnings last quarter?

Alimera Sciences, Inc. (NASDAQ:ALIM) released its quarterly earnings data on Thursday, October, 26th. The biopharmaceutical company reported ($0.06) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.41) by $0.35. The biopharmaceutical company earned $23.36 million during the quarter, compared to the consensus estimate of $24.40 million.

When did Alimera Sciences' stock split?

Alimera Sciences shares reverse split on Friday, November 15th 2019. The 1-15 reverse split was announced on Thursday, November 7th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, November 14th 2019. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

What is Rick Eiswirth's approval rating as Alimera Sciences' CEO?

2 employees have rated Alimera Sciences Chief Executive Officer Rick Eiswirth on Glassdoor.com . Rick Eiswirth has an approval rating of 100% among the company's employees. This puts Rick Eiswirth in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Alimera Sciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Alimera Sciences investors own include EyePoint Pharmaceuticals (EYPT) , OPKO Health (OPK) , VBI Vaccines (VBIV) , Aldeyra Therapeutics (ALDX) , Advanced Micro Devices (AMD) , Amarin (AMRN) , AngloGold Ashanti (AU) , SSR Mining (SSRM) , ADMA Biologics (ADMA) and Cellectar Biosciences (CLRB) .

Who are Alimera Sciences' major shareholders?

Alimera Sciences' stock is owned by a variety of retail and institutional investors. Top institutional investors include Stonepine Capital Management LLC (7.60%), AIGH Capital Management LLC (4.53%), Worth Venture Partners LLC (1.13%), Tower Research Capital LLC TRC (0.02%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Adam Morgan, Alto Investors Lp Palo, Caligan Partners Lp, James R Largent , John Philip Jones , Philip Ashman , Richard S Eiswirth Jr and Stanley Morgan. View institutional ownership trends .

How do I buy shares of Alimera Sciences?

Shares of ALIM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

Alimera Sciences Stock Price, News & Analysis (NASDAQ:ALIM)

$3.08

-0.06 (-1.91%)

(As of 11/30/2023 ET)

Compare

Today's Range: $2.95
▼
$3.28
50-Day Range: $2.63
▼
$3.50
52-Week Range: $1.30
▼
$3.90

Volume: 66,385 shs
Average Volume: 29,789 shs
Market Capitalization: $161.72 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $6.50

Alimera Sciences MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 110.7% Upside
$6.50 Price Target
Short Interest: Bearish
0.30% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.94
Based on 2 Articles This Week
Insider Trading: Acquiring Shares
$1.96 M Bought Last Quarter
Proj. Earnings Growth: -77.78%
From $0.54 to $0.12 Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.06 out of 5 stars

Medical Sector

545th out of 948 stocks

Pharmaceutical Preparations Industry

265th out of 444 stocks

3.5

Analyst's Opinion

Consensus Rating
Alimera Sciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $6.50, Alimera Sciences has a forecasted upside of 110.7% from its current price of $3.09.
Amount of Analyst Coverage
Alimera Sciences has received no research coverage in the past 90 days.

2.0

Short Interest

Percentage of Shares Shorted
0.30% of the outstanding shares of Alimera Sciences have been sold short.
Short Interest Ratio / Days to Cover
Alimera Sciences has a short interest ratio ("days to cover") of 4.2.
Change versus previous month
Short interest in Alimera Sciences has recently increased by 2.81%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
Alimera Sciences does not currently pay a dividend.
Dividend Growth
Alimera Sciences does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for ALIM.

2.7

News and Social Media Coverage

News Sentiment
Alimera Sciences has a news sentiment score of 0.94. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.75 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for Alimera Sciences this week, compared to 2 articles on an average week.
Search Interest
2 people have searched for ALIM on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Alimera Sciences insiders have bought more of their company's stock than they have sold. Specifically, they have bought $1,962,810.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
31.40% of the stock of Alimera Sciences is held by insiders. A high percentage of insider ownership can be a sign of company health.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Alimera Sciences are expected to decrease by -77.78% in the coming year, from $0.54 to $0.12 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Alimera Sciences is -1.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Alimera Sciences is -1.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Alimera Sciences has a P/B Ratio of 3.32. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Alimera Sciences Stock (NASDAQ:ALIM)

Alimera Sciences, Inc., a pharmaceutical company, engages in the development and commercialization of ophthalmic pharmaceuticals. It operates through United States, internationally, and Operating Cost segments. It offers ILUVIEN, an intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and lead to severe vision loss and blindness; and to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye. The company sells its products to physician offices, pharmacies, clinics, and hospitals through direct sales and distributors. It has a collaboration agreement with EyePoint Pharmaceuticals US, Inc. for the development and sale of insert technology to deliver other corticosteroids to the back of the eye for the treatment and prevention of eye diseases in humans or to treat diabetic macular edema. Alimera Sciences, Inc. was incorporated in 2003 and is headquartered in Alpharetta, Georgia.

ALIM Stock Price History

30 days | 90 days | 365 days | Advanced Chart

ALIM Stock News Headlines

November 29, 2023 | americanbankingnews.com

StockNews.com Begins Coverage on Alimera Sciences (NASDAQ:ALIM)

November 8, 2023 | finance.yahoo.com

Alimera Appoints Maggie A. Pax to Its Board of Directors

December 1, 2023 | Edge On The Street (Ad)

Is Gold Really Boring?

Many investors perceive gold as a "boring" investment. But according to MoneyWeek, that's a good thing. Gold helps investors sleep soundly as it preserves wealth and creates a hedge against inflation. Today, there's a unique way to invest in gold, with real advantages over coins and mining stocks.

October 31, 2023 | finance.yahoo.com

Alimera Announces Scientific Data Highlighting ILUVIEN® To Be Presented at the American Academy of Ophthalmology

October 27, 2023 | finance.yahoo.com

Alimera Sciences, Inc. (NASDAQ:ALIM) Q3 2023 Earnings Call Transcript

October 27, 2023 | markets.businessinsider.com

Alimera Sciences Reports Third Quarter 2023 Results

October 26, 2023 | msn.com

Alimera Sciences GAAP EPS of -$0.06 misses by $0.18, revenue of $23.4M beats by $0.68M

October 26, 2023 | finanznachrichten.de

Alimera Sciences, Inc.: Alimera Sciences Reports Third Quarter 2023 Results

December 1, 2023 | Edge On The Street (Ad)

Is Gold Really Boring?

October 26, 2023 | finance.yahoo.com

Alimera Sciences Inc (ALIM) Reports Q3 2023 Financial Results

October 25, 2023 | msn.com

Alimera Sciences Q3 2023 Earnings Preview

October 16, 2023 | finance.yahoo.com

Alimera Sciences to Report Third Quarter 2023 Financial Results on October 26, 2023, and Provide Corporate Update

October 11, 2023 | finance.yahoo.com

Alimera Announces Multiple Presentations Highlighting ILUVIEN® and YUTIQ® Data at Retina Society Annual Congress

October 6, 2023 | finance.yahoo.com

With 47% ownership, Alimera Sciences, Inc. (NASDAQ:ALIM) has piqued the interest of hedge funds investors

October 5, 2023 | benzinga.com

Board Member at Alimera Sciences Acquires Company Stock Options Worth 50,000 Shares

October 3, 2023 | finanznachrichten.de

Alimera Sciences, Inc.: Alimera Sciences Appoints Jason Werner as Chief Operating Officer

October 3, 2023 | finance.yahoo.com

Alimera Sciences Appoints Jason Werner as Chief Operating Officer

September 14, 2023 | finance.yahoo.com

Alimera Sciences, Inc.'s (NASDAQ:ALIM) Profit Outlook

September 5, 2023 | finance.yahoo.com

Alimera Sciences to Present at the H.C. Wainwright 25th Annual Global Investment Conference

August 23, 2023 | finance.yahoo.com

Altium Capital Management LP Acquires New Stake in Alimera Sciences Inc

August 18, 2023 | finance.yahoo.com

Shareholders in Alimera Sciences (NASDAQ:ALIM) are in the red if they invested five years ago

August 14, 2023 | markets.businessinsider.com

The Latest Analyst Ratings for Alimera Sciences

August 13, 2023 | finance.yahoo.com

Alimera Sciences, Inc. (NASDAQ:ALIM) Q2 2023 Earnings Call Transcript

August 11, 2023 | finance.yahoo.com

Stonepine Capital Management, LLC Acquires New Stake in Alimera Sciences Inc

August 11, 2023 | finance.yahoo.com

Q2 2023 Alimera Sciences Inc Earnings Call

August 10, 2023 | finanznachrichten.de

Alimera Sciences, Inc.: Alimera Sciences Reports Second Quarter 2023 Results

August 10, 2023 | markets.businessinsider.com

Here's what Wall Street expects from Alimera Sciences's earnings report

See More Headlines

Receive ALIM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Alimera Sciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 10/26/2023
Today: 12/01/2023
Fiscal Year End: 12/31/2023
Next Earnings (Estimated): 3/29/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:ALIM
CUSIP: N/A
CIK: 1267602
Web: www.alimerasciences.com
Phone: (678) 990-5740
Fax: 678-990-5744
Employees: 150
Year Founded: 2003

Price Target and Rating

Average Stock Price Target: $6.50
High Stock Price Target: $8.00
Low Stock Price Target: $5.00
Potential Upside/Downside: +110.7%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($2.63)
Trailing P/E Ratio: N/A
Forward P/E Ratio: 5.71
P/E Growth: N/A
Net Income: $-18,110,000.00
Net Margins: -29.40%
Pretax Margin: -29.29%
Return on Equity: N/A
Return on Assets: -13.05%

Debt

Debt-to-Equity Ratio: 1.31
Current Ratio: 2.73
Quick Ratio: 2.63

Sales & Book Value

Annual Sales: $54.13 million
Price / Sales: 2.99
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.93 per share
Price / Book: 3.32

Miscellaneous

Outstanding Shares: 52,420,000
Free Float: 35,958,000
Market Cap: $161.72 million
Optionable: Optionable
Beta: 1.43

Social Links

7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Key Executives

Mr. Richard S. Eiswirth Jr. (Age 55)
President, CEO & Director
Comp: $597.87k
Mr. David R. Holland (Age 59)
Co-Founder, Chief Marketing Officer and Senior VP of Corporate Communications & Managed Markets
Comp: $413.5k
Dr. Philip Ashman Ph.D. (Age 58)
President of International Operations
Comp: $389.86k
Mr. Russell L. Skibsted M.B.A. (Age 64)
Senior VP & CFO
Mr. Jason Werner
Chief Operating Officer
Christopher S. Visick
VP, General Counsel & Secretary
Dr. David Dyer M.D.
Chief Retina Specialist

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

ALIM Stock Analysis - Frequently Asked Questions

Should I buy or sell Alimera Sciences stock right now?: 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Alimera Sciences in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ALIM shares.
View ALIM analyst ratings or view top-rated stocks.
What is Alimera Sciences' stock price target for 2024?: 2 equities research analysts have issued 12 month target prices for Alimera Sciences' stock. Their ALIM share price targets range from $5.00 to $8.00. On average, they expect the company's stock price to reach $6.50 in the next year. This suggests a possible upside of 110.7% from the stock's current price.
View analysts price targets for ALIM or view top-rated stocks among Wall Street analysts.
How have ALIM shares performed in 2023?: Alimera Sciences' stock was trading at $2.71 at the beginning of 2023. Since then, ALIM stock has increased by 13.8% and is now trading at $3.0850.
View the best growth stocks for 2023 here.
When is Alimera Sciences' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Friday, March 29th 2024.
View our ALIM earnings forecast.
How were Alimera Sciences' earnings last quarter?: Alimera Sciences, Inc. (NASDAQ:ALIM) released its quarterly earnings data on Thursday, October, 26th. The biopharmaceutical company reported ($0.06) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.41) by $0.35. The biopharmaceutical company earned $23.36 million during the quarter, compared to the consensus estimate of $24.40 million.
When did Alimera Sciences' stock split?: Alimera Sciences shares reverse split on Friday, November 15th 2019. The 1-15 reverse split was announced on Thursday, November 7th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, November 14th 2019. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

What is Rick Eiswirth's approval rating as Alimera Sciences' CEO?: 2 employees have rated Alimera Sciences Chief Executive Officer Rick Eiswirth on Glassdoor.com. Rick Eiswirth has an approval rating of 100% among the company's employees. This puts Rick Eiswirth in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.
What other stocks do shareholders of Alimera Sciences own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Alimera Sciences investors own include EyePoint Pharmaceuticals (EYPT), OPKO Health (OPK), VBI Vaccines (VBIV), Aldeyra Therapeutics (ALDX), Advanced Micro Devices (AMD), Amarin (AMRN), AngloGold Ashanti (AU), SSR Mining (SSRM), ADMA Biologics (ADMA) and Cellectar Biosciences (CLRB).
Who are Alimera Sciences' major shareholders?: Alimera Sciences' stock is owned by a variety of retail and institutional investors. Top institutional investors include Stonepine Capital Management LLC (7.60%), AIGH Capital Management LLC (4.53%), Worth Venture Partners LLC (1.13%), Tower Research Capital LLC TRC (0.02%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Adam Morgan, Alto Investors Lp Palo, Caligan Partners Lp, James R Largent, John Philip Jones, Philip Ashman, Richard S Eiswirth Jr and Stanley Morgan.
View institutional ownership trends.
How do I buy shares of Alimera Sciences?: Shares of ALIM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:ALIM) was last updated on 12/1/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial